Fate Therapeutics Company
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.
Investors
Connections from
Total Funding:
$360.2M
Headquarters:
United States
Funding Status:
IPO
Employee Number:
11-50
Estimated Revenue:
$1M to $10M
Investment Stage:
N/A
Last Funding Type:
Post-IPO Equity
Number Of Exists:
N/A
Technology:
mHealth
Investor Type:
N/A
Investors Number:
7
Founded Date:
2007
Industry:
Genomic and Epigenominc Instabillity